ASCO Highlights

At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA. Read More ›

Results from the ARROW study show that pralsetinib demonstrates broad and durable antitumor activity across multiple advanced solid tumor types, regardless of RET fusion genotype. Read More ›

Results from the ARROW study showed that pralsetinib has rapid, potent, and durable clinical activity in patients with advanced RET fusion–positive non–small-cell lung cancer, regardless of RET fusion genotype or prior therapies. Read More ›

The AcceleRET Lung study will evaluate the efficacy and safety of pralsetinib compared with standard of care for first-line treatment of patients with advanced/metastatic RET fusion–positive non–small-cell lung cancer. Read More ›

Results from the phase 2 GEOMETRY mono-1 study confirm capmatinib to be efficacious in second-line treatment of patients with MET exon 14–mutated non–small-cell lung cancer. Read More ›

An updated analysis of 3 phase 1/2 trials finds that entrectinib continues to demonstrate clinically meaningful responses in patients with NTRK fusion–positive solid tumors, including those with and without baseline central nervous system disease. Read More ›

The next-generation RET inhibitor TPX-0046 demonstrates potent in vitro and in vivo activity against a diverse range of RET alterations, including solvent front mutation–mediated resistance. Read More ›

Selpercatinib (LOXO-292) use was associated with durable antitumor activity in patients with RET-mutant medullary thyroid cancer previously treated with cabozantinib and/or vandetanib as well as in cabozantinib/vandetanib-naïve patients. Read More ›

In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time. Read More ›

Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with EGFR exon20ins-mutated non–small-cell lung cancer. Read More ›